Global Adenomyosis Treatment

Adenomyosis Treatment Comprehensive Study by Type (Focal, Adenomyoma, Diffuse, Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Treatment (Anti-inflammatory Drugs (ibuprofen, Motrin IB, Advil, and others), Hormone Medications (Gonadotropin-releasing hormone (GnRH) agonists, Aromatase inhibitors), Hysterectomy (supra cervical or subtotal hysterectomy, Total hysterectomy, Radical hysterectomy), Others), Diagnosis (Endometrial Biopsy, Ultrasound (transabdominal, transvaginal/endovaginal), Magnetic Resonance Imaging (MRI)) Players and Region - Global Market Outlook to 2028

Adenomyosis Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Adenomyosis Treatment
Adenomyosis often goes away after menopause, so treatment might depend on how close you are to that stage of life. Treatment options for adenomyosis include: Anti-inflammatory drugs. Your doctor might recommend anti-inflammatory medications, such as ibuprofen (Advil, Motrin IB, others), to control the pain. adenomyosis causes diffuse, often fingerlike projections of tissue to invade the uterine wall, we can't just go in and remove the abnormal tissue like we might be able to do with fibroids The demand is growing due to the rising prevalence of adenomyosis. The rising prevalence of adenomyosis disorder is a major driver of market expansion. The global adenomyosis market is being driven by increasing awareness about the disease and treatment, new medications and therapies, and advanced medical technology. Growing research and development funding to produce more innovative products for the market is another choice.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Adenomyosis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bayer AG (Germany), Ferring B.V. (Switzerland), Johnson & Johnson Consumer Inc. (United States), Novartis (Switzerland), Merck KGaA (Germany), Pfizer Inc. (United States), Speciality European Pharma (United Kingdom), AbbVie (United States), Bayer AG (Germany) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Astellas Pharma Inc. (Japan), Mylan N.V. (Netherlands) and Endo Pharmaceuticals (Ireland).

Segmentation Overview
AMA Research has segmented the market of Global Adenomyosis Treatment market by Type (Focal, Adenomyoma, Diffuse and Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers and Others) and Region.



On the basis of geography, the market of Adenomyosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Anti-inflammatory Drugs (ibuprofen, Motrin IB, Advil, and others) will boost the Adenomyosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Endometrial Biopsy will boost the Adenomyosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growth in the Use of Advanced Technology

Market Growth Drivers:
Increasing Knowledge on Novel Drugs and Therapies and Rising Prevalence of Adenomyosis Disorder

Challenges:
Lack of Awareness among the Consumer

Restraints:
Side Effects of the Treatment and High Cost of the Treatment

Opportunities:
Developing Healthcare Infrastructure and Increasing Healthcare Expenditure in Developing Countries and Increasing Funding for R&D to Develop more Advanced Product

Market Leaders and their expansionary development strategies
In September 2023, Hologic, a medical technology company, acquired Acessa Health, a developer of minimally invasive gynecological surgery devices. This acquisition expands Hologic's portfolio of treatment options for adenomyosis, including Acessa's endometrial ablation technology.
In October 2023, Viveve Medical introduces the Viveve System, a non-invasive radiofrequency device for treating pain symptoms of Adenomyosis. This outpatient procedure aims to reduce endometrial tissue thickness and alleviate pain.


Key Target Audience
Adenomyosis Treatment drugs manufacturers, Adenomyosis Treatment drugs providers, Hospitals and clinics, Medical Research laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers and Potential Investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Focal
  • Adenomyoma
  • Diffuse
  • Others
By Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others
By Treatment
  • Anti-inflammatory Drugs (ibuprofen, Motrin IB, Advil, and others)
  • Hormone Medications (Gonadotropin-releasing hormone (GnRH) agonists, Aromatase inhibitors)
  • Hysterectomy (supra cervical or subtotal hysterectomy, Total hysterectomy, Radical hysterectomy)
  • Others

By Diagnosis
  • Endometrial Biopsy
  • Ultrasound (transabdominal, transvaginal/endovaginal)
  • Magnetic Resonance Imaging (MRI)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Knowledge on Novel Drugs and Therapies
      • 3.2.2. Rising Prevalence of Adenomyosis Disorder
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Consumer
    • 3.4. Market Trends
      • 3.4.1. Growth in the Use of Advanced Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adenomyosis Treatment, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Adenomyosis Treatment (Value)
      • 5.2.1. Global Adenomyosis Treatment by: Type (Value)
        • 5.2.1.1. Focal
        • 5.2.1.2. Adenomyoma
        • 5.2.1.3. Diffuse
        • 5.2.1.4. Others
      • 5.2.2. Global Adenomyosis Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Adenomyosis Treatment by: Treatment (Value)
        • 5.2.3.1. Anti-inflammatory Drugs (ibuprofen, Motrin IB, Advil, and others)
        • 5.2.3.2. Hormone Medications (Gonadotropin-releasing hormone (GnRH) agonists, Aromatase inhibitors)
        • 5.2.3.3. Hysterectomy (supra cervical or subtotal hysterectomy, Total hysterectomy, Radical hysterectomy)
        • 5.2.3.4. Others
      • 5.2.4. Global Adenomyosis Treatment by: Diagnosis (Value)
        • 5.2.4.1. Endometrial Biopsy
        • 5.2.4.2. Ultrasound (transabdominal, transvaginal/endovaginal)
        • 5.2.4.3. Magnetic Resonance Imaging (MRI)
      • 5.2.5. Global Adenomyosis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Adenomyosis Treatment (Price)
      • 5.3.1. Global Adenomyosis Treatment by: Type (Price)
  • 6. Adenomyosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ferring B.V. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Consumer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck KGaA (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Speciality European Pharma (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Adenomyosis Treatment Sale, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Adenomyosis Treatment (Value)
      • 7.2.1. Global Adenomyosis Treatment by: Type (Value)
        • 7.2.1.1. Focal
        • 7.2.1.2. Adenomyoma
        • 7.2.1.3. Diffuse
        • 7.2.1.4. Others
      • 7.2.2. Global Adenomyosis Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Adenomyosis Treatment by: Treatment (Value)
        • 7.2.3.1. Anti-inflammatory Drugs (ibuprofen, Motrin IB, Advil, and others)
        • 7.2.3.2. Hormone Medications (Gonadotropin-releasing hormone (GnRH) agonists, Aromatase inhibitors)
        • 7.2.3.3. Hysterectomy (supra cervical or subtotal hysterectomy, Total hysterectomy, Radical hysterectomy)
        • 7.2.3.4. Others
      • 7.2.4. Global Adenomyosis Treatment by: Diagnosis (Value)
        • 7.2.4.1. Endometrial Biopsy
        • 7.2.4.2. Ultrasound (transabdominal, transvaginal/endovaginal)
        • 7.2.4.3. Magnetic Resonance Imaging (MRI)
      • 7.2.5. Global Adenomyosis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Adenomyosis Treatment (Price)
      • 7.3.1. Global Adenomyosis Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adenomyosis Treatment: by Type(USD Million)
  • Table 2. Adenomyosis Treatment Focal , by Region USD Million (2017-2022)
  • Table 3. Adenomyosis Treatment Adenomyoma , by Region USD Million (2017-2022)
  • Table 4. Adenomyosis Treatment Diffuse , by Region USD Million (2017-2022)
  • Table 5. Adenomyosis Treatment Others , by Region USD Million (2017-2022)
  • Table 6. Adenomyosis Treatment: by Application(USD Million)
  • Table 7. Adenomyosis Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 8. Adenomyosis Treatment Clinics , by Region USD Million (2017-2022)
  • Table 9. Adenomyosis Treatment Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 10. Adenomyosis Treatment Others , by Region USD Million (2017-2022)
  • Table 11. Adenomyosis Treatment: by Treatment(USD Million)
  • Table 12. Adenomyosis Treatment Anti-inflammatory Drugs (ibuprofen, Motrin IB, Advil, and others) , by Region USD Million (2017-2022)
  • Table 13. Adenomyosis Treatment Hormone Medications (Gonadotropin-releasing hormone (GnRH) agonists, Aromatase inhibitors) , by Region USD Million (2017-2022)
  • Table 14. Adenomyosis Treatment Hysterectomy (supra cervical or subtotal hysterectomy, Total hysterectomy, Radical hysterectomy) , by Region USD Million (2017-2022)
  • Table 15. Adenomyosis Treatment Others , by Region USD Million (2017-2022)
  • Table 16. Adenomyosis Treatment: by Diagnosis(USD Million)
  • Table 17. Adenomyosis Treatment Endometrial Biopsy , by Region USD Million (2017-2022)
  • Table 18. Adenomyosis Treatment Ultrasound (transabdominal, transvaginal/endovaginal) , by Region USD Million (2017-2022)
  • Table 19. Adenomyosis Treatment Magnetic Resonance Imaging (MRI) , by Region USD Million (2017-2022)
  • Table 20. South America Adenomyosis Treatment, by Country USD Million (2017-2022)
  • Table 21. South America Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 22. South America Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 23. South America Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 24. South America Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 25. Brazil Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 26. Brazil Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 27. Brazil Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 28. Brazil Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 29. Argentina Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 30. Argentina Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 31. Argentina Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 32. Argentina Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 33. Rest of South America Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 35. Rest of South America Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 36. Rest of South America Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 37. Asia Pacific Adenomyosis Treatment, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 40. Asia Pacific Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 41. Asia Pacific Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 42. China Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 43. China Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 44. China Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 45. China Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 46. Japan Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 47. Japan Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 48. Japan Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 49. Japan Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 50. India Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 51. India Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 52. India Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 53. India Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 54. South Korea Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 55. South Korea Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 56. South Korea Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 57. South Korea Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 58. Taiwan Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 59. Taiwan Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 60. Taiwan Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 61. Taiwan Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 62. Australia Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 63. Australia Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 64. Australia Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 65. Australia Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 70. Europe Adenomyosis Treatment, by Country USD Million (2017-2022)
  • Table 71. Europe Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 72. Europe Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 73. Europe Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 74. Europe Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 75. Germany Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 76. Germany Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 77. Germany Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 78. Germany Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 79. France Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 80. France Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 81. France Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 82. France Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 83. Italy Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 84. Italy Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 85. Italy Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 86. Italy Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 87. United Kingdom Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 89. United Kingdom Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 90. United Kingdom Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 91. Netherlands Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 92. Netherlands Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 93. Netherlands Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 94. Netherlands Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 95. Rest of Europe Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 97. Rest of Europe Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 98. Rest of Europe Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 99. MEA Adenomyosis Treatment, by Country USD Million (2017-2022)
  • Table 100. MEA Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 101. MEA Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 102. MEA Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 103. MEA Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 104. Middle East Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 105. Middle East Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 106. Middle East Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 107. Middle East Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 108. Africa Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 109. Africa Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 110. Africa Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 111. Africa Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 112. North America Adenomyosis Treatment, by Country USD Million (2017-2022)
  • Table 113. North America Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 114. North America Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 115. North America Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 116. North America Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 117. United States Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 118. United States Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 119. United States Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 120. United States Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 121. Canada Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 122. Canada Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 123. Canada Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 124. Canada Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 125. Mexico Adenomyosis Treatment, by Type USD Million (2017-2022)
  • Table 126. Mexico Adenomyosis Treatment, by Application USD Million (2017-2022)
  • Table 127. Mexico Adenomyosis Treatment, by Treatment USD Million (2017-2022)
  • Table 128. Mexico Adenomyosis Treatment, by Diagnosis USD Million (2017-2022)
  • Table 129. Adenomyosis Treatment: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Adenomyosis Treatment: by Type(USD Million)
  • Table 141. Adenomyosis Treatment Focal , by Region USD Million (2023-2028)
  • Table 142. Adenomyosis Treatment Adenomyoma , by Region USD Million (2023-2028)
  • Table 143. Adenomyosis Treatment Diffuse , by Region USD Million (2023-2028)
  • Table 144. Adenomyosis Treatment Others , by Region USD Million (2023-2028)
  • Table 145. Adenomyosis Treatment: by Application(USD Million)
  • Table 146. Adenomyosis Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 147. Adenomyosis Treatment Clinics , by Region USD Million (2023-2028)
  • Table 148. Adenomyosis Treatment Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 149. Adenomyosis Treatment Others , by Region USD Million (2023-2028)
  • Table 150. Adenomyosis Treatment: by Treatment(USD Million)
  • Table 151. Adenomyosis Treatment Anti-inflammatory Drugs (ibuprofen, Motrin IB, Advil, and others) , by Region USD Million (2023-2028)
  • Table 152. Adenomyosis Treatment Hormone Medications (Gonadotropin-releasing hormone (GnRH) agonists, Aromatase inhibitors) , by Region USD Million (2023-2028)
  • Table 153. Adenomyosis Treatment Hysterectomy (supra cervical or subtotal hysterectomy, Total hysterectomy, Radical hysterectomy) , by Region USD Million (2023-2028)
  • Table 154. Adenomyosis Treatment Others , by Region USD Million (2023-2028)
  • Table 155. Adenomyosis Treatment: by Diagnosis(USD Million)
  • Table 156. Adenomyosis Treatment Endometrial Biopsy , by Region USD Million (2023-2028)
  • Table 157. Adenomyosis Treatment Ultrasound (transabdominal, transvaginal/endovaginal) , by Region USD Million (2023-2028)
  • Table 158. Adenomyosis Treatment Magnetic Resonance Imaging (MRI) , by Region USD Million (2023-2028)
  • Table 159. South America Adenomyosis Treatment, by Country USD Million (2023-2028)
  • Table 160. South America Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 161. South America Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 162. South America Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 163. South America Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 164. Brazil Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 165. Brazil Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 166. Brazil Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 167. Brazil Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 168. Argentina Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 169. Argentina Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 170. Argentina Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 171. Argentina Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 172. Rest of South America Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 173. Rest of South America Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 174. Rest of South America Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 175. Rest of South America Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 176. Asia Pacific Adenomyosis Treatment, by Country USD Million (2023-2028)
  • Table 177. Asia Pacific Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 178. Asia Pacific Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 179. Asia Pacific Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 180. Asia Pacific Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 181. China Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 182. China Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 183. China Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 184. China Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 185. Japan Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 186. Japan Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 187. Japan Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 188. Japan Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 189. India Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 190. India Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 191. India Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 192. India Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 193. South Korea Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 194. South Korea Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 195. South Korea Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 196. South Korea Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 197. Taiwan Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 198. Taiwan Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 199. Taiwan Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 200. Taiwan Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 201. Australia Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 202. Australia Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 203. Australia Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 204. Australia Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 209. Europe Adenomyosis Treatment, by Country USD Million (2023-2028)
  • Table 210. Europe Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 211. Europe Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 212. Europe Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 213. Europe Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 214. Germany Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 215. Germany Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 216. Germany Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 217. Germany Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 218. France Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 219. France Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 220. France Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 221. France Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 222. Italy Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 223. Italy Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 224. Italy Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 225. Italy Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 226. United Kingdom Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 227. United Kingdom Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 228. United Kingdom Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 229. United Kingdom Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 230. Netherlands Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 231. Netherlands Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 232. Netherlands Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 233. Netherlands Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 234. Rest of Europe Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 235. Rest of Europe Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 236. Rest of Europe Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 237. Rest of Europe Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 238. MEA Adenomyosis Treatment, by Country USD Million (2023-2028)
  • Table 239. MEA Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 240. MEA Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 241. MEA Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 242. MEA Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 243. Middle East Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 244. Middle East Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 245. Middle East Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 246. Middle East Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 247. Africa Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 248. Africa Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 249. Africa Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 250. Africa Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 251. North America Adenomyosis Treatment, by Country USD Million (2023-2028)
  • Table 252. North America Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 253. North America Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 254. North America Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 255. North America Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 256. United States Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 257. United States Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 258. United States Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 259. United States Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 260. Canada Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 261. Canada Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 262. Canada Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 263. Canada Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 264. Mexico Adenomyosis Treatment, by Type USD Million (2023-2028)
  • Table 265. Mexico Adenomyosis Treatment, by Application USD Million (2023-2028)
  • Table 266. Mexico Adenomyosis Treatment, by Treatment USD Million (2023-2028)
  • Table 267. Mexico Adenomyosis Treatment, by Diagnosis USD Million (2023-2028)
  • Table 268. Adenomyosis Treatment: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adenomyosis Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Adenomyosis Treatment: by Application USD Million (2017-2022)
  • Figure 6. Global Adenomyosis Treatment: by Treatment USD Million (2017-2022)
  • Figure 7. Global Adenomyosis Treatment: by Diagnosis USD Million (2017-2022)
  • Figure 8. South America Adenomyosis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Adenomyosis Treatment Share (%), by Country
  • Figure 10. Europe Adenomyosis Treatment Share (%), by Country
  • Figure 11. MEA Adenomyosis Treatment Share (%), by Country
  • Figure 12. North America Adenomyosis Treatment Share (%), by Country
  • Figure 13. Global Adenomyosis Treatment: by Type USD/Units (2017-2022)
  • Figure 14. Global Adenomyosis Treatment share by Players 2022 (%)
  • Figure 15. Global Adenomyosis Treatment share by Players (Top 3) 2022(%)
  • Figure 16. Global Adenomyosis Treatment share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 20. Ferring B.V. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Ferring B.V. (Switzerland) Revenue: by Geography 2022
  • Figure 22. Johnson & Johnson Consumer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Johnson & Johnson Consumer Inc. (United States) Revenue: by Geography 2022
  • Figure 24. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 26. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 28. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 30. Speciality European Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Speciality European Pharma (United Kingdom) Revenue: by Geography 2022
  • Figure 32. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 33. AbbVie (United States) Revenue: by Geography 2022
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 36. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 38. Global Adenomyosis Treatment: by Type USD Million (2023-2028)
  • Figure 39. Global Adenomyosis Treatment: by Application USD Million (2023-2028)
  • Figure 40. Global Adenomyosis Treatment: by Treatment USD Million (2023-2028)
  • Figure 41. Global Adenomyosis Treatment: by Diagnosis USD Million (2023-2028)
  • Figure 42. South America Adenomyosis Treatment Share (%), by Country
  • Figure 43. Asia Pacific Adenomyosis Treatment Share (%), by Country
  • Figure 44. Europe Adenomyosis Treatment Share (%), by Country
  • Figure 45. MEA Adenomyosis Treatment Share (%), by Country
  • Figure 46. North America Adenomyosis Treatment Share (%), by Country
  • Figure 47. Global Adenomyosis Treatment: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Ferring B.V. (Switzerland)
  • Johnson & Johnson Consumer Inc. (United States)
  • Novartis (Switzerland)
  • Merck KGaA (Germany)
  • Pfizer Inc. (United States)
  • Speciality European Pharma (United Kingdom)
  • AbbVie (United States)
  • Bayer AG (Germany)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Teva Pharmaceutical Industries Ltd. (Israel) , Novartis AG (Switzerland) , Astellas Pharma Inc. (Japan) , Mylan N.V. (Netherlands) , Endo Pharmaceuticals (Ireland)
Select User Access Type

Key Highlights of Report


Dec 2023 210 Pages 86 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Adenomyosis Treatment Quantitative research analysis
Global Adenomyosis Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bayer AG (Germany), Ferring B.V. (Switzerland), Johnson & Johnson Consumer Inc. (United States), Novartis (Switzerland), Merck KGaA (Germany), Pfizer Inc. (United States), Speciality European Pharma (United Kingdom), AbbVie (United States), Bayer AG (Germany) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growth in the Use of Advanced Technology" is seen as one of major influencing trends for Adenomyosis Treatment Market during projected period 2022-2028.
The Adenomyosis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Adenomyosis Treatment Report?

Have a Query? Click Here

Other Related Reports

Aneurysmal Subarachnoid Hemorrhage Comprehensive Study by Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography, Transcranial Dop...
$ 3650
Phenylketonuria Treatment Comprehensive Study by Type (Drugs (Kuvan, Pegvaliase and Others), Dietary Supplement), Application (Hospital Pharmacies, Drug Stores, Online Pharmacies, Pediatric Clinics),...
$ 3650
Nerve Repair and Regeneration Comprehensive Study by Type (Neurostimulation Devices, Neuromodulation Devices (Sacral Nerve Stimulation Devices (SNS), Vagus Nerve Stimulation Devices (VNS), Spinal Cor...
$ 3750
mRNA Vaccines & Therapeutics Comprehensive Study by Type (Standardization of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, In...
$ 3750
Antibody Services Comprehensive Study by Type (Polyclonal antibody, Monoclonal antibody, Murine, Chimeric, Humanize, Other), Application (Gastroenterology, Rheumatology, Infection, Cardiology, Hemato...
$ 3650
Liver Disease Treatment Comprehensive Study by Application (Hospital, Clinic, Others), Disease Type (Hepatitis, Autoimmune diseases, Liver tumor, Chronic liver disease, Fatty liver disease.), Treatme...
$ 3650